Patents will not stand in the way of producing the drug for mankind.
Our pharmaceuticals division gained additional market share, with all major products contributing to this strong performance, particularly our new cancer medicines.
I maintain the belief that it is not that easy or productive or value-creating going for a mega-merger.
We're learning from the mistakes we make.
We will talk to anybody -- people who can manufacture the drug, and are able to manufacture it faster than us, and complement our manufacturing.
It became a drug which was difficult to commercialize, ... We sat there with a drug in which we had invested a significant amount of development and where we had sales that were less than exciting.
This unprecedented transaction significantly strengthens our position, as it enables Roche to become a leader in the second-largest pharmaceuticals market worldwide and adds global access to Chugai's solid research and development pipeline.
I would say that we would see an acceleration (in drug sales), especially in the second half of the year, with the introduction of new products, with the acceleration also of the penetration of the oncology line in the non-U.S. markets.
If I look at what we have in the product pipeline, and what we have licensed in, I maintain our stance that we can manage with organic growth.
Copyright © 2024 Electric Goat Media. All Rights Reserved.